GlaxoSmithKline is to drench its cold drinks brands with a £100m investment this year.

The giant spend, up from £79m last year, will be ploughed into its Ribena and Lucozade propositions and will include funding for new products.

Plans for product launches are being kept under wraps, but it is understood that limited edition variants under both banners are likely to feature, all of which could end up becoming permanent fixtures if they score a hit with consumers.

Full details in this week’s issue of The Grocer.